The present invention relates to stable formulations comprising antibodies or antigen-binding fragments thereof that bind to respiratory syncytial virus (RSV). Also provided are methods of preventing and/or treating RSV-related diseases with the formulations of the invention.

Provided are a highly-sensitive antibody and a test reagent using the antibody. A method for detecting an analyte according to an immunoassay method, using a carrier on which an antigen, an antibody or an antigen-binding fragment thereof is immobilized, wherein the analyte is detected with increasing detection sensitivity by using a carrier to which an antigen, an antibody or an antigen-binding fragment thereof was immobilized by adding disaccharide and sugar alcohol to a solution comprising an antigen, an antibody or an antigen-binding fragment thereof.

Provided is an anti-Henipavirus monoclonal antibody having broad spectrum neutralization activity, wherein the antibody comprises a macaque variable region and a human constant region. The antibody of the present invention has good binding activity to both Nipah virus glycoprotein G and Hendra virus glycoprotein G, can effectively neutralize Nipahpseudovirus and Hendra pseudovirus, and can be used for preparing drugs for treating Henipavirus diseases.

Systems and methods to genetically modify B cells to express selected antibodies are described. The systems and methods can be used to: obviate the need for classical vaccinations; provide protection against infectious agents for which no vaccinations are currently available; provide protection against infectious agents when patients are otherwise immune-suppressed; and/or provide a benefit provided by a therapeutic antibody, such as in the treatment of autoimmune disorders.

Provided are epitope-specific antigen-binding molecules specific to a human metapneumovirus (hMPV) Fusion (F) protein, in which the antigen-binding molecule comprises a variable domain that contacts the hMPV F protein. The antigen-binding molecule specific to an hMPV F protein comprises a heavy chain and a light chain. Further provided are methods for detecting antibodies specific to an hMPV F protein, a method comprising: a.) contacting a biological sample with an hMPV F protein; and b.) contacting an epitope-specific antigen-binding molecule with the hMPV F protein.

Provided are epitope-specific antigen-binding molecules specific to a human metapneumovirus (hMPV) Fusion (F) protein, in which the antigen-binding molecule comprises a variable domain that contacts the hMPV F protein. The antigen-binding molecule specific to an hMPV F protein comprises a heavy chain and a light chain. Further provided are methods for detecting antibodies specific to an hMPV F protein, a method comprising: a.) contacting a biological sample with an hMPV F protein; and b.) contacting an epitope-specific antigen-binding molecule with the hMPV F protein.

Formulations containing pH-sensitive nanoparticles for the enteric delivery of therapeutic agents are provided. The nanoparticles include a pH-sensitive polymer that protects the therapeutic agent against degradation in the stomach and allows it to be released in the small intestine or colon. The nanoparticle formulation is particularly effective at protecting sensitive biotherapeutic agents from degradation when administered orally, and makes it possible to avoid administration of such agents by injection. Also provided are methods for producing the formulations, as well as methods of treating diseases employing the formulations.

The disclosure relates to ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. Specific embodiments relate to RNA betacoronavirus vaccines formulated in a lipid nanoparticle.

The present invention relates to an improved method of producing products comprising a target protein (TP) capable of crystallising under salting-in conditions by crystallisation of the TP. The invention makes use of at least two different TP-containing protein feeds which are mixed to prepare a supersaturated protein solution in which TP is crystallized. One of the protein feeds must have a pH of at least the pH providing the maximum crystallisation yield of the TP (pH.sub.MCY,TP) plus 0.1 and one of the protein feeds must have a pH of at most pH.sub.MCY,TP minus 0.1.

The present invention relates to an improved method of producing products comprising a target protein (TP) capable of crystallising under salting-in conditions by crystallisation of the TP. The invention makes use of at least two different TP-containing protein feeds which are mixed to prepare a supersaturated protein solution in which TP is crystallized. One of the protein feeds must have a pH of at least the pH providing the maximum crystallisation yield of the TP (pH.sub.MCY,TP) plus 0.1 and one of the protein feeds must have a pH of at most pH.sub.MCY,TP minus 0.1.